A Nature Medicine study documented 4-1BB-costimulated CD19 CAR-T cells up to 10 years after infusion in adults with B-cell non-Hodgkin lymphoma. Among eight evaluable patients who remained in remission beyond five years, the CAR…
Investigators deeply profiled anti-CD19 CAR-T products and leukapheresis starting material from the phase I/II HD-CAR-1 dose-escalation study. Among 28 treated patients, six achieved responses despite receiving low doses. These low-dose responders were enriched for…
The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory follicular lymphoma. The approval is supported by the Phase 3 EPCORE FL-1 trial, where TEPKINLY…
